SCHEMBL29105804

SCHEMBL29105804

CCC[C@H]1CCC(=O)N1C(=O)OC(C)(C)C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 2/20 0.45
ALDH1A1 P00352 1/20 0.41
KMT2A Q03164 1/20 0.41
CHRM2 P08172 1/20 0.39
CHRM1 P11229 1/20 0.39
CHRM3 P20309 1/20 0.39
DDB1 Q16531 2/20 0.36
CRBN Q96SW2 2/20 0.36
GLA P06280 1/20 0.35
KLK7 P49862 6/20 0.34
ELANE P08246 1/20 0.34
KLK5 Q9Y337 5/20 0.34
KDM4E B2RXH2 1/20 0.34
MAPT P10636 1/20 0.34
THRB P10828 1/20 0.34
PRSS1 P07477 2/20 0.33
PRSS2 P07478 2/20 0.33
PRSS3 P35030 2/20 0.33
NR1H2 P55055 1/20 0.33
PARP1 P09874 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29105806 1.00 ATM (0.45) ATMALDH1A1KMT2ACHRM2CHRM1
SCHEMBL627060 0.88 CHRM2 (0.39) ATMALDH1A1KMT2ACHRM2CHRM1
SCHEMBL20371561 0.88 CHRM2 (0.41) ATMALDH1A1KMT2ACHRM2CHRM1
SCHEMBL11917911 0.88 CHRM2 (0.41) ATMALDH1A1KMT2ACHRM2CHRM1
SCHEMBL24250115 0.85 NR1H2 (0.41) ATMCHRM2CHRM1CHRM3DDB1
SCHEMBL13482907 0.85 NR1H2 (0.41) ATMCHRM2CHRM1CHRM3DDB1
SCHEMBL12531180 0.85 NR1H2 (0.41) ATMCHRM2CHRM1CHRM3DDB1
SCHEMBL18901856 0.84 CHRM2 (0.40) ATMCHRM2CHRM1CHRM3DDB1
SCHEMBL14230420 0.84 CHRM2 (0.40) ATMCHRM2CHRM1CHRM3DDB1
SCHEMBL10263362 0.84 CHRM2 (0.40) ATMCHRM2CHRM1CHRM3DDB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250026736-A1 3-(5-oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione Derivatives and Uses thereof NOVARTIS AG (CH) 2025-01-23 US disclosed
US-12103919-B2 3-(5-oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof NOVARTIS AG (CH) 2024-10-01 US disclosed
CN-117062811-A 3- (1-oxo-isoindolin-2-yl) piperidine-2, 6-dione derivatives and medical use thereof 诺华股份有限公司 2023-11-14 CN disclosed
US-20230019617-A1 3-(5-oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione Derivatives and Uses thereof NOVARTIS AG (CH) 2023-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250026736-A1 3-(5-oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione Derivatives and Uses thereof HBZ, HBG1, HBG2 ATM 4814/4885ALDH1A1 929/4885KMT2A 910/4885
US-20230019617-A1 3-(5-oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione Derivatives and Uses thereof HBZ, HBG1, HBG2 ATM 4814/4885ALDH1A1 929/4885KMT2A 910/4885
US-12103919-B2 3-(5-oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof HBZ, HBG1, HBG2 ATM 4814/4885ALDH1A1 929/4885KMT2A 910/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.